metricas
covid
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Toxicities from immunotherapy: From clinical trials to real-world clinical pract...
Journal Information

Statistics

Follow this link to access the full text of the article

Review
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
Toxicidades de la inmunoterapia: de los ensayos clínicos a la práctica clínica en el mundo real
Mar Riveiro-Barcielaa,b, Ernesto Trallero-Araguásc, Fernando Martínez-Valled,
Corresponding author
ferranmartinezvalle@gmail.com

Corresponding author.
, on behalf of the Vall d’Hebrón Group for the study of Immunotherapy immune-related adverse events
a Liver Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
c Rheumatology Unit, Hospital Universitari Vall d’Hebron, Barcelona, Spain
d Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain
Vall d’Hebrón Committee for management of Immunotherapy immune-related adverse events
Read
13
Times
was read the article
3
Total PDF
10
Total HTML
Share statistics
 array:24 [
  "pii" => "S2387020620305520"
  "issn" => "23870206"
  "doi" => "10.1016/j.medcle.2020.06.030"
  "estado" => "S300"
  "fechaPublicacion" => "2020-12-25"
  "aid" => "5397"
  "copyright" => "Elsevier España, S.L.U.. All rights reserved"
  "copyrightAnyo" => "2020"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "cita" => "Med Clin. 2020;155:541-7"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S0025775320305741"
      "issn" => "00257753"
      "doi" => "10.1016/j.medcli.2020.06.057"
      "estado" => "S300"
      "fechaPublicacion" => "2020-12-24"
      "aid" => "5397"
      "copyright" => "Elsevier España, S.L.U."
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "rev"
      "cita" => "Med Clin. 2020;155:541-7"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
        "titulo" => "Toxicities from immunotherapy&#58; From clinical trials to real-world clinical practice"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "541"
            "paginaFinal" => "547"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Toxicidades de la inmunoterapia&#58; de los ensayos cl&#237;nicos a la pr&#225;ctica cl&#237;nica en el mundo real"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:2 [
          0 => array:2 [
            "autoresLista" => "Mar Riveiro-Barciela, Ernesto Trallero-Aragu&#225;s, Fernando Mart&#237;nez-Valle"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "Mar"
                "apellidos" => "Riveiro-Barciela"
              ]
              1 => array:2 [
                "nombre" => "Ernesto"
                "apellidos" => "Trallero-Aragu&#225;s"
              ]
              2 => array:2 [
                "nombre" => "Fernando"
                "apellidos" => "Mart&#237;nez-Valle"
              ]
              3 => array:1 [
                "colaborador" => "on behalf of the Vall d&#8217;Hebr&#243;n Group for the study of Immunotherapy immune-related adverse events"
              ]
            ]
          ]
          1 => array:2 [
            "autoresLista" => ""
            "autores" => array:1 [
              0 => array:1 [
                "colaborador" => "Vall d&#8217;Hebr&#243;n Committee for management of Immunotherapy immune-related adverse events"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2387020620305520"
          "doi" => "10.1016/j.medcle.2020.06.030"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620305520?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320305741?idApp=UINPBA00004N"
      "url" => "/00257753/0000015500000012/v1_202012131718/S0025775320305741/v1_202012131718/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2387020620305519"
    "issn" => "23870206"
    "doi" => "10.1016/j.medcle.2020.07.014"
    "estado" => "S300"
    "fechaPublicacion" => "2020-12-25"
    "aid" => "5289"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Med Clin. 2020;155:548-56"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>"
      "titulo" => "Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of <span class="elsevierStyleItalic">IL-6</span> gene polymorphisms in novel coronavirus pneumonia"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "548"
          "paginaFinal" => "556"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Tratamiento con anticuerpos anti-receptor de IL-6 para COVID-19 grave y la posible implicaci&#243;n de polimorfismos del gen IL-6 en la nueva neumon&#237;a por coronavirus"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Fig&#46; 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 3386
              "Ancho" => 3167
              "Tamanyo" => 466905
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Association between <span class="elsevierStyleItalic">IL-6</span> &#8722;174G&#47;C polymorphism with the severity of pneumonia&#46; &#40;A&#41; C vs&#46; G&#59; &#40;B&#41; CC&#43;GC vs&#46; GG&#59; &#40;C&#41; CC vs&#46; GG&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Zulvikar Syambani Ulhaq, Gita Vita Soraya"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Zulvikar Syambani"
              "apellidos" => "Ulhaq"
            ]
            1 => array:2 [
              "nombre" => "Gita Vita"
              "apellidos" => "Soraya"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0025775320304498"
        "doi" => "10.1016/j.medcli.2020.07.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320304498?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620305519?idApp=UINPBA00004N"
    "url" => "/23870206/0000015500000012/v1_202012131835/S2387020620305519/v1_202012131835/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2387020620305416"
    "issn" => "23870206"
    "doi" => "10.1016/j.medcle.2020.05.029"
    "estado" => "S300"
    "fechaPublicacion" => "2020-12-25"
    "aid" => "5204"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Med Clin. 2020;155:538-40"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial article</span>"
      "titulo" => "Predicting risk indices of recurrence in the unprovoked venous thromboembolic disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "538"
          "paginaFinal" => "540"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "&#205;ndices de riesgo de recurrencia en la enfermedad tromboemb&#243;lica venosa no provocada"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Juan J&#46; L&#243;pez-N&#250;&#241;ez, Patricia Sig&#252;enza"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Juan J&#46;"
              "apellidos" => "L&#243;pez-N&#250;&#241;ez"
            ]
            1 => array:2 [
              "nombre" => "Patricia"
              "apellidos" => "Sig&#252;enza"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0025775320302906"
        "doi" => "10.1016/j.medcli.2020.05.008"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320302906?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620305416?idApp=UINPBA00004N"
    "url" => "/23870206/0000015500000012/v1_202012131835/S2387020620305416/v1_202012131835/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
    "titulo" => "Toxicities from immunotherapy&#58; From clinical trials to real-world clinical practice"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "541"
        "paginaFinal" => "547"
      ]
    ]
    "autores" => array:2 [
      0 => array:4 [
        "autoresLista" => "Mar Riveiro-Barciela, Ernesto Trallero-Aragu&#225;s, Fernando Mart&#237;nez-Valle"
        "autores" => array:4 [
          0 => array:3 [
            "nombre" => "Mar"
            "apellidos" => "Riveiro-Barciela"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Ernesto"
            "apellidos" => "Trallero-Aragu&#225;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Fernando"
            "apellidos" => "Mart&#237;nez-Valle"
            "email" => array:1 [
              0 => "ferranmartinezvalle@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          3 => array:2 [
            "colaborador" => "on behalf of the Vall d&#8217;Hebr&#243;n Group for the study of Immunotherapy immune-related adverse events"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Liver Unit&#44; Internal Medicine Department&#44; Hospital Universitari Vall d&#8217;Hebron&#44; Universitat Autonoma de Barcelona&#44; Barcelona&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Hep&#225;ticas y Digestivas &#40;CIBERehd&#41;&#44; Instituto de Salud Carlos III&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Rheumatology Unit&#44; Hospital Universitari Vall d&#8217;Hebron&#44; Barcelona&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Systemic Autoimmune Diseases Unit&#44; Internal Medicine Department&#44; Hospital Universitari Vall d&#8217;Hebron&#44; Barcelona&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
      1 => array:2 [
        "autoresLista" => ""
        "autores" => array:1 [
          0 => array:1 [
            "colaborador" => "Vall d&#8217;Hebr&#243;n Committee for management of Immunotherapy immune-related adverse events"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Toxicidades de la inmunoterapia&#58; de los ensayos cl&#237;nicos a la pr&#225;ctica cl&#237;nica en el mundo real"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Immunotherapy has become an important pillar of cancer care&#44; complementing surgery&#44; cytotoxic therapy and radiotherapy in most tumour types&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">1</span></a> Description of the immune-editing by Schreiber as a process that enables escape from immune surveillance to establish overt malignancy<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">2</span></a> and description of cancer-immunity cycle by Chen and Mellman impacted on the development of multiple opportunities for therapeutic intervention that enhance tumour immunity&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">3</span></a> Immune check-point inhibitors &#40;CPI&#41; that target the programmed death protein 1 pathway &#40;anti-PD-1&#58; nivolumab and pembrolizumab&#41; and its ligand &#40;anti-PD-L1&#58; atezolizumab&#44; avelumab and durvalumab&#41; have generated the most interesting strategy with response rates across tumour types that average 20&#8211;30&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">1</span></a> The other group of CPI are the anti cytotoxic T-lymphocyte-associated antigen &#40;anti-CTLA-4&#58; ipilimumab and tremelimumab&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">4</span></a> These drugs engage T cells with inherent capacity for adaptability and memory that lead to durable responses and long-term survival is observed&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Safety profile of CPI differs from chemotherapy and immune-related adverse events &#40;irAEs&#41; result from immune activation driving autoimmune manifestations&#46; Overall&#44; the majority of patients treated with CPI developed any irAEs&#44; though the rate of grade 3 events is much lower &#40;around 10&#37;&#41;&#44; rate higher with combinations&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">5</span></a> They usually present within the first weeks of CPI&#44; though they can occur anytime&#46; For the effective management of irAEs&#44; early diagnosis is critical&#46;<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">6&#8211;8</span></a> Herein we present a comprehensive review on management of main irAEs associated with immunotherapy&#44; focusing not only on the current guidelines but real-world data&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Gastrointestinal immune-related adverse events</span><p id="par0015" class="elsevierStylePara elsevierViewall">Gastrointestinal symptoms are the most common adverse events reported by patients treated with CPI&#44; especially within the six first months of treatment&#44; with rates of 45&#37; of diarrhoea and 19&#37; increase of alanine aminotransferase &#40;ALT&#41; when nivolumab and ipilimumab are combined&#44;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">9</span></a> though a wide spectrum of sympthons has been described&#46; Importance of gastrointestinal irAEs lies not in its overall prevalence&#44; but in the considerable percentage of patients who present grade &#40;G&#41;3 or 4 adverse events&#44; with colitis and hepatitis as the irAEs reported more frequently&#44; with rates of 8&#37; and 9&#37; of patients treated with a combination of CPI&#46;<a class="elsevierStyleCrossRefs" href="#bib0345"><span class="elsevierStyleSup">9&#44;10</span></a></p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Immune-related hepatitis</span><p id="par0020" class="elsevierStylePara elsevierViewall">Asymptomatic increase of aspartate aminotransferase &#40;AST&#41; or ALT is a common analytical finding in patients undergoing therapy with CPI&#44; especially in those treated with anti-CTLA-4 agents&#46; In the <span class="elsevierStyleItalic">CheckMate 238</span>&#44; the rate of patients who experienced any degree of increased ALT levels was 14&#46;6&#37; among those treated with ipilimumab&#44; in contrast to 6&#46;2&#37; for those who received nivolumab&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">11</span></a> This difference was also observed in case of severe ALT increase &#40;5&#46;7&#37; vs 1&#46;1&#37;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">11</span></a> Incidence of acute liver failure has been reported to be as infrequent as 0&#46;04&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">12</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Immune-mediated hepatitis presentation ranges from asymptomatic increase ALT and AST levels to acute liver failure&#46; As with the vast majority of irAEs&#44; its diagnosis lies in the exclusion of other causes of acute hepatitis such as drugs or viral hepatitis&#44;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> especially Hepatitis B virus infection since cases of reactivation have been described&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">13</span></a> Moreover&#44; imaging is mandatory to rule out progression of the underlying malignancy&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> To date&#44; the role of liver biopsy is one of the hot topics concerning immune-mediated hepatitis&#46; According to the ESMO guidelines&#44; it may be useful in assisting in the differential diagnosis of severe hepatitis or refractory cases&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> However real-world data has revealed the usefulness of liver biopsy showing specific findings according to the type of CPI &#40;granulomatous hepatitis with endothelitis for anti-CTLA-4 agents and lobular hepatitis for anti-PD1&#47;PD-L&#41; and suggesting a relationship between the grade of lobular activity and the need of treatment with corticoids&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">14</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Management depends on its severity&#44; ranging from neither specific therapy nor CPI discontinuation for G1 toxicity &#40;AST<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>ALT<span class="elsevierStyleHsp" style=""></span>&#62;3x Upper limit of normality-ULN&#41;&#44; withholding of immunotherapy with close analytical monitoring for G2 &#40;AST<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>ALT 3&#8211;5xULN&#41; to corticosteroids for G3 and 4 hepatitis at dose of 1&#8211;2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg per day plus addition of mycophenolate mofetil &#40;MMF&#41; at 72<span class="elsevierStyleHsp" style=""></span>h in absence of improvement&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> Though corticosteroids have been the backbone for therapy of the most severe cases of immune-mediated hepatitis&#44; a few real-world series have shown that interruption of immunotherapy without addition of immunosuppressant drugs can be a safe alternative in 38&#8211;50&#37; of patients with G3 or 4 hepatitis&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">14</span></a> However&#44; avoidance of corticosteroids is not an option in those cases presenting with increased bilirubin levels or signs of liver failure such as INR<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>1&#46;5&#46; Moreover&#44; acute liver failure may be treated aggressively so that liver transplantation is not a feasible choice&#46; In this setting&#44; plasma exchange or antithymocyte globulin therapy have been identified as useful options in addition to corticosteroids plus MMF&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">15</span></a> As opposed to colitis&#44; infliximab is not recommended&#44; thought it has been recently reported as a safe option in isolated cases&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">16</span></a> Differences between guidelines and proposed real-world management are summarized in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Another controversial issue is the re-introduction of immunotherapy after an episode of immune-mediated hepatitis&#46; The FDA as well as the main Oncology societies recommends the permanent discontinuation of CPI in case of G3 or 4 immune-mediated hepatitis&#46;<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">6&#44;8</span></a> Although it is well known that patients who have already developed an irAE are more prone to present another&#44; there is growing real-world evidence supporting the re-introduction of immunotherapy&#44; especially in those patients with no alternative options of treatment &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0385"><span class="elsevierStyleSup">17&#8211;19</span></a> To date there is no available data concerning the risk of flares in patients with underlying autoimmune hepatitis when they are exposed to CPI&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Immune-related colitis</span><p id="par0040" class="elsevierStylePara elsevierViewall">Diarrhoea is one of the most common irAEs reported in patients undergoing CPI&#44; especially anti-CTLA-4&#46;<a class="elsevierStyleCrossRefs" href="#bib0345"><span class="elsevierStyleSup">9&#44;10</span></a> The use in solitary of ipilimumab has been associated with higher risk of both diarrhoea &#40;27&#8211;54&#37;&#41; and colitis &#40;8&#8211;22&#37;&#41; than anti-PD-1&#47;PD-L1 in monotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">11</span></a> Moreover&#44; colitis is the leading cause for anti-CTLA-4 discontinuation&#44; with an estimated mortality of 1&#37;&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Though its presentation is highly variable&#44; the hallmark of immune-mediated colitis is diarrhoea&#44; and in a lower rate abdominal pain&#44; fever&#44; and rectal blood loss&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">20</span></a> In all patients undergoing CPI&#44; especially anti-CTLA-4&#44; stool culture and <span class="elsevierStyleItalic">Clostridium difficile</span> toxin testing should be performed in case of severe diarrhoea&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> Endoscopy with biopsy is mandatory to confirm the diagnosis and rule out cytomegalovirus infection or presence of metastasis&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> Though extensive colitis has been described in two thirds of patients&#44; the sigmoid colon and rectum is present in up to 97&#37; of patients so a flexible sigmoidoscopy is usually enough to confirm the diagnosis of immune-mediated colitis&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">21</span></a> Real-world data from patients who developed diarrhoea on immunotherapy have suggested a poor correlation between the grade of diarrhoea and endoscopic or histological features for severity of colitis&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">22</span></a> However&#44; presence of ulcers or a pancolitis were associated with need for infliximab in 76&#8211;79&#37; of cases&#44; supporting the usefulness of early endoscopy for patients treated with CPI presenting with diarrhoea&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">22</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">G1 colitis can usually be managed conservatively&#44; with resolution of symptoms by treatment with loperamide or codeine without recourse to stopping CPI&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">23</span></a> However&#44; treatment of choice for G3 or more severe colitis or G2 with systemic symptoms is corticosteroids plus CPI withdrawal&#46; In case of lack of improvement in 72<span class="elsevierStyleHsp" style=""></span>h&#44; infliximab at dose of 5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg is recommended&#44; with a single dose usually sufficient to control colitis&#46;<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">21&#44;24</span></a> In case of non-response&#44; endoscopic re-evaluation&#44; including new biopsies for ruling out cytomegalovirus infection are highly recommended before repeating infliximab infusions&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">23</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Many patients&#44; particularly with combination-induced colitis&#44; tolerated anti-PD-1 rechallenge well&#44; so this approach can be considered in selected patients &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46; Recently&#44; a large series including 167 patients with immune-mediated diarrhoea and colitis&#44; 57 &#40;34&#37;&#41; recurred&#44; especially if retreatment with an anti-CTLA-4 agent&#46;<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">25</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Another important issue is treatment with CPI in patients with underlying inflammatory bowel disease &#40;IBD&#41;&#46; To date experience is scarce and provided by retrospective studies showing a rate of relapse ranging from 0 to 33&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0430"><span class="elsevierStyleSup">26&#44;27</span></a> Based on this data&#44; pre-existing IBD cannot be considered a contraindication for immunotherapy&#44; though previous endoscopic assessment and avoidance of concomitant non steroidal anti-inflammatory drugs would be highly recommended&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">23</span></a></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Endocrine system immune-related adverse events</span><p id="par0065" class="elsevierStylePara elsevierViewall">Up to 10&#37; of patients treated with immunotherapy will present an irAE involving the endocrine glands&#44; especially when CPIs are used in combination&#46;<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">28</span></a> In case of monotherapy&#44; anti-PD1&#47;PD-L1 has been associated with higher risk of thyroid dysfunction whereas anti-CTLA-4 treatment was more commonly linked to hypophysitis&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">29</span></a> The spectrum of endocrine disorders is wide &#40;12 endocrinopathies affecting 5 different glands&#41;&#44; with hypopituitarism&#44; thyroid disorders and diabetes mellitus being the most frequent&#46; Although in many cases presentation is asymptomatic&#44; on the other hand&#44; life-threatening cases have been reported&#44; so monitoring of patients is recommended during treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a></p><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Immune-related hypophysitis</span><p id="par0070" class="elsevierStylePara elsevierViewall">Hypophysitis has been reported basically in patients treated with an anti-CTLA-4&#44; with an incidence ranging from 0&#46;4 to 17&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">30</span></a> Onset of symptoms is usually 12 weeks after the beginning of CPI&#44;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">31</span></a> though cases within the first month of therapy have also been described&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">The symptoms are usually nonspecific and derived from the hormonal defect such as fatigue and&#47;or muscle weakness&#44; reported in up to 89&#37; of subjects&#44; or due to the compression caused by the growth of the pituitary&#44; leading to headache and visual disturbance&#46;<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">28</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">It is recommended to perform a baseline TSH determination and during follow-up in patients treated with CPI&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> If symptoms of hypophysitis appear&#44; the patient should be evaluated early through the determination of ACTH&#44; cortisol&#44; TSH and T4&#44; and also gonadotropins and sex hormones&#44; since reports of diabetes insipidus&#44; hypogonadotropic hypogonadism&#44; IGF1 deficiency and prolactin increase has been observed&#46;<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">28</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">In case of hypophysitis G<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>2&#44; defined as moderate symptoms&#44; CPI might be discontinued&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> High dose corticosteroids treatment is indicated in patients with severe disease&#44; but in most cases&#44; the symptoms can be quickly resolved with low doses of corticosteroids&#46;<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">32</span></a> In a study including 177 patients treated with immunotherapy&#44; 11 &#40;6&#37;&#41; cases of hypophysitis were observed&#46; Five of them were asymptomatic&#44; 5 developed symptoms and 1 debuted as an adrenal crisis&#46; Interestingly&#44; patients treated with combination CPI were more prone to symptomatic presentation in comparison with those treated with ipilimumab &#40;83&#37; vs 20&#37;&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;036&#41;&#46; All of them were treated with corticosteroids &#40;5&#8211;7&#46;5<span class="elsevierStyleHsp" style=""></span>mg prednisone&#41;&#44; and immunotherapy was not discontinued in any of the patients&#46; No cases of secondary adrenal insufficiency or secondary hypothyroidism normalized&#44; though secondary hypogonadism normalized without treatment in up to 27&#37; of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">33</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Immune-related thyroid involvement</span><p id="par0090" class="elsevierStylePara elsevierViewall">Thyroid disorders occur more frequently after administration of anti-PD-1&#47;PD-L1 alone &#40;1&#8211;6&#37;&#41; or in combination with anti-CTLA-4 &#40;9&#46;9&#8211;22&#37;&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">10&#44;28</span></a> The spectrum of symptoms is highly variable&#44; from asymptomatic to thyrotoxic crisis&#46; The diagnosis is established by the presence of high levels of TSH with low or normal values of free T3 and free T4&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> Presence of thyroid autoantibodies is relatively low&#46;<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">34</span></a> Since thyroid disorders associated with immunotherapy are often an analytical finding in the context of nonspecific symptoms such as fatigue&#44; thyroid function must be monitored before the start of immunotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> In case of hypothyroidism hormone replacement is recommended&#44; whereas hyperthyroidism usually resolves spontaneously&#44; with the subsequent appearance of hypothyroidism&#46; In severe cases&#44; it is indicated to suspend CPI treatment until the resolution of symptoms with later re-introduction of CPI&#46;<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">35</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Immune-related diabetes mellitus</span><p id="par0095" class="elsevierStylePara elsevierViewall">The incidence of diabetes mellitus &#40;DM&#41; after treatment with immunotherapy is low &#40;&#60;1&#37;&#41; and seems to be more frequent after administration of anti-PD-1&#47;PD-L1 or its combination with ipilimumab&#46; Two main mechanisms of development have been described&#58; destruction of pancreatic B cells leading to type 1 DM&#44; and induction of insulin resistance in case of type 2 DM&#46;<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">36</span></a> The diagnosis of type 1 DM is based on clinical and analytical findings and through the determination of antibodies against glutamic acid decarboxylase and islet cells which are detected in more than 50&#37; of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">37</span></a> Patients who developed DM presented with rapid-onset hyperglycemia within days to weeks after the first dose of nivolumab or pembrolizumab&#44; which evolved to life-threatening complications like diabetic ketoacidosis&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">37</span></a> Periodic glucose determination should be performed in patients treated with CPI&#46; Insulin treatment is recommended in patients who develop type 1 DM&#46;<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">35</span></a> Immunotherapy can be resumed once glycemic control is established&#44; and in most cases long-term insulin maintenance is necessary&#46;</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Rheumatic immune-related adverse events</span><p id="par0100" class="elsevierStylePara elsevierViewall">There is great evidence to consider joint manifestations&#44; including arthralgia and inflammatory arthritis &#40;IA&#41;&#44; as one of the most frequent rheumatic irAEs in patients on CPI&#46; However&#44; although a recent systematic review reported a frequency of IA between 1 and 7&#37;&#44;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> real incidence remains unknown since classification of rheumatic irAEs has not been consistent in clinical trials&#46;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> Despite the fact IA is not a life-threatening side effect it can critically affect the patient&#39;s quality of life&#46; Hence&#44; strategies to guarantee an early identification and treatment of IA are needed&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Although there is scant information about pathogenesis of CPI-induced IA&#44; genetic background probably plays an important role at least in some cases&#46; Cappelli et al&#46; reported 20&#37; of patients with CPI-induced IA had a first degree relative with autoimmune disease&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">39</span></a> CPI can also act as a trigger of a pre-clinical inflammatory joint disease&#46; Nevertheless&#44; this is not a common clinical setting&#44; as most patients with IA are seronegative for RF or ACPAs&#46; Finally&#44; patients with previously diagnosed inflammatory arthritis &#40;i&#46;e&#46; RA&#44; psoriatic arthritis&#41; seem to have an increased risk of disease flare in the setting of CPI<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">26</span></a> &#40;40&#8211;50&#37;&#41;&#44; especially when they are combined&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Pattern of joint involvement is very heterogeneous&#44; and it has been linked with the immunotherapy regimen&#58; patients receiving monotherapy usually show small joint involvement at onset&#44; whereas those on combined CPI are more likely to have knee involvement first with small joints preserved&#46;<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">40</span></a> Mean time to onset of joint symptoms after initiation of immunotherapy is variable&#44; within 12 and 26 weeks&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">41</span></a> Nevertheless&#44; arthritis onset can even occur several months after CPI discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">41</span></a> Coexistence of other irAEs is frequent and can occur in almost 70&#37; of patients who develop IA&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">39</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">Nowadays there is limited data to guide treatment decisions in CPI-induced IA&#46; For G1 and 2 IA&#44; NSAIDs and medium doses of corticosteroids &#40;&#8804;20<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;&#44; are usually recommended&#46; Intra-articular steroids are useful in cases of mono-oligoarthritis&#46; For refractory patients or G3 to 4 IA&#44; guidelines recommend the use of high doses of prednisone &#40;0&#46;5&#8211;1<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">8</span></a> Contrary to these strategies&#44; recent studies have reported complete responses in patients with polyarthritis using lower doses of corticosteroids&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">41</span></a> Of note&#44; contrary to other irAEs&#44; CPI-induced IA can be more persistent even after CPI discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">42</span></a> These findings support the need for continued immunosuppression may be more relevant to IA than other irAEs&#44; and therefore&#44; the use of corticosteroid-sparing agents more necessary&#46; Synthetic disease-modifying antirheumatic drugs &#40;DMARDs&#41; are the most commonly corticosteroid-sparing agents used in CPI-induced IA&#46; Methothrexate has demonstrated to be effective in several cases of CPI-induced IA&#46;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">43</span></a> Although recommended in guidelines&#44; experience with leflunomide has scarcely been reported&#46; Hydroxycloroquine &#40;HCQ&#41; at a dose of 200&#8211;400<span class="elsevierStyleHsp" style=""></span>mg&#47;day &#40;based on weight&#41;&#44; could be an interesting alternative according to the results of a recent pilot study where seven out of ten patients achieved complete resolution of their joint swelling and pain within the first two months of treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">41</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">In patients with severe symptoms or with a poor response to synthetic DMARDs&#44; biologic treatment is recommended&#46; Anti-TNF&#945; and tocilizumab are the biologics most commonly used&#46;<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">44</span></a> In general&#44; biologics can reach peak efficacy more quickly than DMARDs&#46; However&#44; preclinical data demonstrated that TNF&#945; inhibition may dampen CPI therapy antitumour benefits&#46; In favour of the use of tocilizumab&#44; IL-6 signalling pathway has been shown to play a role in the tumorigenesis of multiple cancers&#44; associated with worse prognosis&#44; and resistance to chemotherapy&#47;immunotherapy&#46; Nowadays&#44; efficacy of tocilizumab in CPI-related IA has been only reported in a small number of cases&#46;<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">44</span></a> Of note&#44; tocilizumab has been associated with bowel perforation in patients with diverticulitis&#44; so may not be a good choice if prior CPI-related colitis&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Immune-related muscular involvement</span><p id="par0125" class="elsevierStylePara elsevierViewall">Musculoskeletal phenotypes are also vaguely documented&#46; In a recent review by Cappelli et al&#46; myalgia was the second most reported musculoskeletal irAE&#44; with an incidence ranging from 2 to 21&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">39</span></a> Myositis occured in 1&#37; of patients treated with anti-PD-1&#47;PD-L1 agents with one fatality in the adjuvant pembrolizumab trial and in &#60;1&#37; of ipilimumab treated patients&#46;<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">45</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">Muscular side effects include musculoskeletal pain&#44; inflammatory myositis&#44; polymyalgia rheumatica &#40;PMR&#41; syndrome characterized by severe pain and stiffness affecting the shoulders and pelvic girdle bilaterally&#44; ocular myositis and myasthenia-like syndrome&#46; Also&#44; autoimmune myocarditis is more common than previously thought&#44; and it can manifest in different ways such as cardiovascular death&#44; cardiogenic shock&#44; cardiac arrest and complete heart block&#46;<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">46</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Inflammatory myositis is a heterogeneous group of chronic conditions characterized by muscle inflammation associated with motor weakness&#46; CPI-associated myositis harbours distinct clinical features that differentiate it from idiopathic myositis&#44; such as a more acute onset&#44; the occurrence of ocular myasthenia-like symptoms &#40;ptosis and oculomotor weakness with diplopia&#41;&#44; a higher frequency of myocarditis and a poor prognosis with higher mortality rates&#46;<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">47</span></a> While some patients are highly symptomatic with severe pain with no creatinkinase &#40;CK&#41; elevation&#44; others are asymptomatic&#44; with only CK elevation as a sign of muscular involvement&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">48</span></a> Thirty-one to 65&#37; of patients present with increased CK&#44; however myositis-associated antibodies and myositis-specific antibodies are usually negative&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">48</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">Muscle biopsy findings range from nonspecific myopathy to inflammatory myopathies resembling dermatomyositis and necrotizing autoimmune myopathy&#46; Since up to 30&#37; of patients with CPI-myositis present concomitant myocarditis&#44; it is important to perform an echocardiography in order to rule out this complication&#46;<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">49</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Myositis is graded according to the current oncologic guidelines<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">8</span></a>&#58; G1 refers to a mild weakness with or without pain&#44; G2 is a moderate weakness with or without pain&#44; limiting age appropriate activity&#44; G3 and G4 weakness is severe&#44; with or without pain&#44; limiting daily activity&#46; In G2&#44; 3 and 4 CK usually is elevated&#46; Maintain treatment with CPI can be considered in G1 or in G2 if the CK is normal&#46; For mild or moderate myalgias&#44; analgesia with paracetamol and&#47;or NSAIDs is recommended&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> Steroids at dose of 0&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;d may be additionally considered for moderate symptoms&#44; while high-dose steroids and&#47;or other steroid-sparing drugs may be needed for severe symptoms &#40;1&#8211;1&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#41;&#46; Moreira et al&#46; describe a better outcome in patients that received treatment with steroids&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">48</span></a> Patients presenting with severe myositis &#40;G3 or 4&#41; can require treatment with intravenous immunoglobulin at the same doses as other types of inflammatory myopathies&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">8</span></a> If symptoms and CK levels do not improve or worsen after 4&#8211;6 weeks&#44; another immunosuppressant therapy&#44; like azathioprine&#44; methotrexate or MMF&#44; should be considered&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">8</span></a> For severe myocarditis Salem et al&#46; have recently reported the efficacy of intravenous Abatacept &#40;a CTLA-4 agonist&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">50</span></a> Patients affected with PMR-like syndrome usually respond to low dose corticosteroids&#44; however there are cases which required treatment with tocilizumab&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">48</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">Globally&#44; half of the cases resolve under treatment&#46; Sequelae can exist in 16&#37; of patients&#46;<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">48</span></a> Patients with severe myositis cannot be retreated&#44; however this could be an option with those with mild symptoms and normal CK values&#46; However&#44; it should be highlighted that the only case of ventricular arrhythmias reported in the cohort by Santini et al&#46; relapsed after reintroduction of CPI&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">51</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Neurological immune-related adverse events</span><p id="par0155" class="elsevierStylePara elsevierViewall">Neurological irAEs are heterogeneous and include central and peripheral nervous system involvement&#46; To date&#44; Myasthenia gravis &#40;MG&#41;&#44; Guillain-Barr&#233; syndrome&#44; meningo-radiculo-neuritis&#44; demyelinating polyradiculoneuropathies&#44; encephalitis&#44; granulomatous central nervous system inflammation&#44; vasculitis&#44; aseptic meningitis and multiple sclerosis have been described&#44; with MG as the most frequent&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a> MG can present de novo in most patients&#44; however up to 27&#37; of patients with myasthenia-like syndrome may be related to exacerbations of pre-existing or sub-clinical MG&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">Incidence of immune-related neurological irAEs is lower than 1&#37; in patients undergoing anti-PD-1&#47;PD-L1&#44;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">53</span></a> and few cases are associated with ipilimumab&#46; The importance of neurological irAEs lies in its severity&#44; since these entities are usually life-threatening&#44; with an estimated mortality of 30&#46;4&#37;&#44;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a> emphasizing the need for early diagnosis and treatment&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">When a neurological irAE is suspected&#44; magnetic resonance imaging is recommended&#46; Lumbar puncture may also be helpful&#44; especially to rule out other neurological complications such as infections&#46; In the case of MG&#44; the anti&#8211;acetylcholine receptor &#40;AChR&#41; antibodies are present in 59&#37; of patients&#44; and its presence has been identified with better prognosis&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a> Approximately 47&#37; of patients with MG present elevated CK levels suggestive of muscle inflammation&#44; thus muscular biopsy usually does not appear to be consistent with inflammatory myositis&#46;<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">54</span></a> Combination of MG and myocarditis has also been described in patients treated with nivolumab&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Treatment for G1-2 neurological irAEs consists in delaying immunotherapy&#44; starting prednisone at 0&#46;5&#8211;1<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day and tapering sequentially until resolution of symptoms&#44; with later possibility of restart of CPI&#46; In G<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>3 toxicity&#44; prednisone at 1&#8211;2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day should be initiated in addition to permanent discontinuation of CPI&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> In patients with MG or myositis&#47;MG syndrome treatment with corticosteroid and the acetylcholinesterase inhibitor pyridostigmine are mandatory&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a> In case of severe symptoms intravenous immunoglobulins and plasmapheresis may improved prognosis&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> The few reports of severe neurologic toxicity that were retreated with CPI did not experience recurrences&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">51</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Pulmonary immune-related adverse events</span><p id="par0175" class="elsevierStylePara elsevierViewall">Pneumonitis is one of the most commonly reported pulmonary irAE with an incidence around 6&#37; in patients receiving anti-PD-1&#47;PD-L1 and 12&#37; in combined CPI&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> Acute interstitial pneumonitis and diffuse alveolar damage are the most frequent and life-threating events&#44; but organizing inflammatory pneumonia as well as sarcoidosis-like lesions have also been described&#46;<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">6&#44;55</span></a> Median time from beginning of CPI to pneumonitis is 3 months&#44; though cases after the first dose have been reported&#46;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">55</span></a> Estimated mortality rate is 12&#37;&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">It is necessary to make a systematic study in patients with respiratory symptoms like dyspnoea or dry cough&#46; A high-resolution computed tomography scan findings are heterogeneous&#44; including ground-glass opacities &#40;37&#37;&#41;&#44; interstitial infiltrates &#40;7&#37;&#41;&#44; cryptogenic organizing pneumonia-like patterns &#40;19&#37;&#41; or hypersensibility &#40;22&#37;&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">6&#44;55</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">The possibility of added complications should be considered&#44; especially respiratory infections or progression of underlying oncological disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">29&#44;55</span></a> Thus&#44; in G<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>3 pneumonitis&#44; bronchoscopy and bronchoalveolar lavage are highly recommended&#46; Lung biopsy is not required except if radiological or clinical concerns about the diagnosis&#46; Histopathologic patterns include acute cellular interstitial pneumonitis&#44; alveolar damage&#44; and organizing pneumonia&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">55&#44;56</span></a></p><p id="par0190" class="elsevierStylePara elsevierViewall">Treatment is based on corticosteroids&#44; initially at dose of 1<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#44; with tapering over no less than 4 weeks when symptoms improve&#46; Broad spectrum antibiotics are highly recommended unless concomitant infection has been reliably ruled out&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> In G<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>3 pneumonitis the patient must be hospitalised and treatment should consist of high dose corticosteroids &#40;2&#8211;4<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#41;&#46; If there is no improvement in 2 days&#44; additional immunosuppression with infliximab &#40;5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#41;&#44; MMF or cyclophosphamide is recommended&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> However&#44; real-world data has suggested the potential role of the addition of either anti-thymocyte globulin or intravenous immunoglobulin for severe refractory pneumonitis&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">29</span></a> Some patients experience recurrent pneumonitis during corticoid therapy after initial clinical improvement&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">Reintroduction of CPI after a severe pneumonitis is controversial and real-world data in this regard scarce &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Renal immune-related adverse events</span><p id="par0200" class="elsevierStylePara elsevierViewall">Renal dysfunction is rare when CPIs are used in monotherapy&#44; though its prevalence increases to 4&#46;9&#37; when they are combined&#46;<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">57</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">Renal toxicity is graded according to creatinine levels&#44; with increase 1&#46;5&#8211;2&#44; 2&#8211;3 and 3-fold over baseline creatine levels stand for G1&#44; 2 and 3&#44; respectively&#46; G4 toxicity can be life-threatening and usually requires dialysis&#46; The timing of onset of acute kidney injury is highly variable&#44; with a median time of 91 days&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">58</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">The underlying mechanism of renal toxicity in the setting of CPI is diverse and therefore a renal biopsy can be considered to clarify the cause&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">58</span></a> The most common finding is nephritis with lymphocytic infiltration&#44; though other entities such as ANCA associated vasculitis&#44; granulomatous nephritis&#44; or thrombotic microangiopathy has been described&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">58</span></a> Renal damage is usually asymptomatic&#44; with the presence of oliguria&#44; pyuria or hypertension infrequent&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">CPI should be withheld in the event of significant renal dysfunction &#40;G<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>2&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">6</span></a> After ruling out other causes of renal injury&#44; the use of systemic corticosteroid therapy should be considered &#40;0&#46;5&#8211;2 mgr&#47;kg&#47;d&#41;&#46; In the series from Cortazar et al&#46; most patients reached a partial or complete response with steroids&#44;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">58</span></a> but in some refractory cases&#44; treatment with other immunosuppressant drugs like MMF can be warranted &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Patients who present microangiopathy in the biopsy can have worse response to treatment&#44; requiring immunosuppression&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">59</span></a> Reinitiating CPI can be considered when the toxicity is less than G2 and if there has been a favourable response to corticosteroids&#46; On the contrary&#44; if severity is G3 or 4 it is important to consider carefully the risk&#47;benefit&#46;<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">59</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">Despite scarce data on patients with chronic kidney disease&#44; therapy with CPI appears to be safe&#46; Patients with renal transplantation are at high risk of rejecting the allograft and requiring dialysis&#46; Some data has shown that anti-CTLA-4 agents are safer that anti-PD-1&#47;PD-L1&#44; for which a near universal rejection has been reported&#46;<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">60</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conclusion</span><p id="par0225" class="elsevierStylePara elsevierViewall">In parallel with their high efficacy rates&#44; immune checkpoint inhibitors have been linked to a large number of immune-related adverse events&#44; with a wide diversity of manifestations and severity&#46; Rising data from real-world cohorts are shedding new light on diagnosis and treatment of these adverse events&#44; emphasizing the need for multidisciplinary management and data on biomarkers for identification of patients at risk prior to the beginning of immunotherapy&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conflict of interest</span><p id="par0230" class="elsevierStylePara elsevierViewall">Authors have no personal interests to declare</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:16 [
        0 => array:3 [
          "identificador" => "xres1433276"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1308284"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1433275"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1308283"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Gastrointestinal immune-related adverse events"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Immune-related hepatitis"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Immune-related colitis"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Endocrine system immune-related adverse events"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Immune-related hypophysitis"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Immune-related thyroid involvement"
            ]
            2 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Immune-related diabetes mellitus"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Rheumatic immune-related adverse events"
        ]
        8 => array:2 [
          "identificador" => "sec0050"
          "titulo" => "Immune-related muscular involvement"
        ]
        9 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Neurological immune-related adverse events"
        ]
        10 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Pulmonary immune-related adverse events"
        ]
        11 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Renal immune-related adverse events"
        ]
        12 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Conclusion"
        ]
        13 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conflict of interest"
        ]
        14 => array:2 [
          "identificador" => "xack500248"
          "titulo" => "Acknowledgments"
        ]
        15 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2020-03-11"
    "fechaAceptado" => "2020-06-02"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1308284"
          "palabras" => array:5 [
            0 => "Immunotherapy"
            1 => "Adverse drugs reaction"
            2 => "Hepatitis"
            3 => "Myositis"
            4 => "Cancer"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1308283"
          "palabras" => array:5 [
            0 => "Inmunoterapia"
            1 => "Reacci&#243;n adversa a los medicamentos"
            2 => "Hepatitis"
            3 => "Miositis"
            4 => "C&#225;ncer"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">In recent years&#44; immunotherapy has become an important pillar of cancer treatment&#44; with high response rates regardless of tumour histology or baseline mutations&#46; However&#44; immune activation associated with check-point inhibitors is not selective and a large variety of immune-related adverse events have been associated with anti-PD1&#44; anti-PD-1&#47;L-1 and anti-CTLA-4 agents&#46; Though diagnosis and treatment of these toxicities have been established according to the recommendations from clinical trials and in line with the autoimmune disorders that they mimic&#44; increasing real-world data is coming up showing that these adverse events may have differential characteristics and management&#44; especially in terms of the use of corticoids&#44; second-line treatments&#44; salvage therapy for life-threatening cases and reintroduction of immunotherapy&#46; Herein we present a comprehensive review of current recommendations and real-world data on the main immune-related adverse events of immunotherapy&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">En los &#250;ltimos a&#241;os la inmunoterapia se ha convertido en un pilar fundamental para el tratamiento del c&#225;ncer&#44; con altas tasas de respuesta&#44; independientemente de la histolog&#237;a tumoral o de las mutaciones basales&#46; Sin embargo&#44; la activaci&#243;n inmune asociada a los inhibidores de control no es selectiva&#44; habi&#233;ndose asociado una gran variedad de efectos adversos relacionados con la inmunidad a los agentes anti-PD1&#44; anti-PD-1&#47;L-1 y anti-CTLA-4&#46; Aunque se han establecido el diagn&#243;stico y el tratamiento de estas toxicidades en virtud de las recomendaciones de los ensayos cl&#237;nicos&#44; en consonancia con los trastornos autoinmunes que imitan&#44; el incremento de los datos del mundo real refleja que dichos efectos adversos pueden tener caracter&#237;sticas y manejos diferenciales&#44; especialmente en t&#233;rminos de uso de corticoides&#44; tratamientos de segunda l&#237;nea&#44; terapia de rescate para casos potencialmente letales&#44; y reintroducci&#243;n de la inmunoterapia&#46; Presentamos aqu&#237; una revisi&#243;n amplia de las recomendaciones actuales y los datos del mundo real sobre los principales efectos adversos de la inmunoterapia&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "&#9674;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Please see a list of the members of the Vall d&#8217;Hebr&#243;n Committee in <a class="elsevierStyleCrossRef" href="#sec0080">Appendix A</a>&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0240" class="elsevierStylePara elsevierViewall">Mar&#237;a Roca-Herrera &#40;Medical Oncology Department&#46; Hospital Universitari Vall d&#8217;Hebron&#44; Barcelona&#44; Spain&#46; Vall d&#8217;hebron Institute of Oncology &#91;VHIO&#93;&#44; Barcelona&#44; Spain&#41;</p> <p id="par0245" class="elsevierStylePara elsevierViewall">Ester Zamora &#40;Medical Oncology Department&#46; Hospital Universitari Vall d&#8217;Hebron&#44; Barcelona&#44; Spain&#46; Vall d&#8217;hebron Institute of Oncology &#91;VHIO&#93;&#44; Barcelona&#44; Spain&#41;</p> <p id="par0250" class="elsevierStylePara elsevierViewall">Ana Barreira-D&#237;az &#40;Liver Unit&#44; Internal Medicine Department&#46; Hospital Universitari Vall d&#8217;Hebron&#44; Barcelona&#44; Spain&#41;</p> <p id="par0255" class="elsevierStylePara elsevierViewall">Eva Mu&#241;oz-Couselo &#40;Medical Oncology Department&#46; Hospital Universitari Vall d&#8217;Hebron&#44; Barcelona&#44; Spain&#46; Vall d&#8217;hebron Institute of Oncology &#91;VHIO&#93;&#44; Barcelona&#44; Spain&#41;</p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Vall d&#8217;Hebr&#243;n Group for the study of Immunotherapy immune-related adverse events"
            "identificador" => "sec0080"
          ]
        ]
      ]
    ]
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="3" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Guidelines recommendation</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="3" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Real-world suggested management</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">CPI discontinuation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Corticoids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Others&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">CPI discontinuation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Corticoids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Others&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hepatitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MMF if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MMF&#44; tacrolimus if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Colitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; vedolizumab if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hypophysitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hormone replacement&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hormone replacement&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hypothyroidism&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hormone replacement&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hormone replacement&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hyperthyroidism&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Beta-blockers&#177; Carbimazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Beta-blockers<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>Carbimazole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Arthritis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti-TNF&#945; agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Metothrexato&#44; anti-TNF&#945;&#44; hydroxycloroquine&#44; tocilizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Myositis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">azathioprine&#44; methotrexate or MMF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ig&#39;s&#44; azathioprine&#44; MMF methotrexate&#44; tocilizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumonitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; MMF or Cyclophosphamide if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; anti-thymocyte globulin or Ig&#39;s if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neurological&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ig&#39;s and plasmapheresis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#177;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pyridostigmine&#44; Ig&#39;s and plasmapheresis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Renal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#10003;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MMF if refractory&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2464341.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">If lobular activity is not severe and bilirubin and clotting are within normal values&#46;</p> <p class="elsevierStyleNotepara" id="npar0010">Check-point inhibitors&#44; CPI&#59; Ig&#39;s&#44; Immunoglobulins&#59; MMF&#44; mycophenolate mofetil&#59; ESMO&#44; European Society for Medical Oncology&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Management of the main grade 3 and 4 immune-mediated adverse events according to the ESMO guidelines in comparison with the current real-world data&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Pollack et al&#46;&#58; Retreatment with an anti-PD-1 agent after an irAE &#40;all grades&#41; with combined anti-CTLA-4 plus anti-PD-1 therapy for metastatic melanoma&#59; Santini et al&#46;&#58; Subjects with non-small cell lung cancer retreated with anti-PD-1&#47;PD-L1 after an irAE that led to immunotherapy &#40;anti-PD-1&#47;PD-L1<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>anti-CTLA-4&#41; discontinuation &#40;all grades&#41;&#59; Simonaggio et al&#46;&#58; Retreatment with anti-PD-1&#47;PD-L1 after an initial grade 2 or higher irAE&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">irAE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pollack et al&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">17</span></a></th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Santini et al&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">51</span></a></th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Simonaggio et al&#46;<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">19</span></a></th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recurrence&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">De-novo<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recurrence&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">De-novo<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recurrence&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">De-novo<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hepatitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#47;29 &#40;17&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;51 &#40;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;3 &#40;33&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;35 &#40;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#47;5 &#40;60&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#47;5 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Colitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;33 &#40;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#47;47 &#40;13&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;7 &#40;29&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#47;31 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#47;5 &#40;60&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#47;5 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumonitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;3 &#40;33&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#47;77 &#40;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;6 &#40;15&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;32 &#40;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;5 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;5 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hypophysitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;8 &#40;13&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;72 &#40;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Skin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;4 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#47;76 &#40;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;5 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;33 &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#47;7 &#40;43&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;7 &#40;14&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Arthralgia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#47;5 &#40;60&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;33 &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#47;6 &#40;83&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;6 &#40;15&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nephritis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;2 &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#47;78 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#47;2 &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#47;36 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2464340.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Cases of the irAE in the cohort of retreated patients who had previously presented a different irAE&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Cases of a different irAE in the cohort of patient who had previously presented the cited irAE&#46;</p> <p class="elsevierStyleNotepara" id="npar0025">irAE&#44; immune-related adverse event&#59; N&#47;A&#44; not available&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Real-world rates of recurrence or de-novo immune-related adverse events &#40;irAEs&#41; in patients who re-challenge immunotherapy after a prior irAE&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:60 [
            0 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antagonists of PD-1 and PD-L1 in cancer treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Lipson"
                            1 => "P&#46;M&#46; Forde"
                            2 => "H&#46;J&#46; Hammers"
                            3 => "L&#46;A&#46; Emens"
                            4 => "J&#46;M&#46; Taube"
                            5 => "S&#46;L&#46; Topalian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.seminoncol.2015.05.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Oncol"
                        "fecha" => "2015"
                        "volumen" => "42"
                        "paginaInicial" => "587"
                        "paginaFinal" => "600"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26320063"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer immunoediting&#58; from immunosurveillance to tumor escape"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "G&#46;P&#46; Dunn"
                            1 => "A&#46;T&#46; Bruce"
                            2 => "H&#46; Ikeda"
                            3 => "L&#46;J&#46; Old"
                            4 => "R&#46;D&#46; Schreiber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ni1102-991"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Immunol"
                        "fecha" => "2002"
                        "volumen" => "3"
                        "paginaInicial" => "991"
                        "paginaFinal" => "998"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12407406"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oncology meets immunology&#58; the cancer-immunity cycle"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "D&#46;S&#46; Chen"
                            1 => "I&#46; Mellman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.immuni.2013.07.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunity"
                        "fecha" => "2013"
                        "volumen" => "39"
                        "paginaInicial" => "1"
                        "paginaFinal" => "10"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23890059"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;F&#46; Krummel"
                            1 => "J&#46;P&#46; Allison"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1084/jem.183.6.2533"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Exp Med"
                        "fecha" => "1996"
                        "volumen" => "183"
                        "paginaInicial" => "2533"
                        "paginaFinal" => "2540"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8676074"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer immunotherapy&#58; opportunities and challenges in the rapidly evolving clinical landscape"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46;A&#46; Emens"
                            1 => "P&#46;A&#46; Ascierto"
                            2 => "P&#46;K&#46; Darcy"
                            3 => "S&#46; Demaria"
                            4 => "A&#46;M&#46;M&#46; Eggermont"
                            5 => "W&#46;L&#46; Redmond"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2017.01.035"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2017"
                        "volumen" => "81"
                        "paginaInicial" => "116"
                        "paginaFinal" => "129"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28623775"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of toxicities from immunotherapy&#58; ESMO Clinical Practice Guidelines for diagnosis&#44; treatment and follow-up"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Haanen"
                            1 => "F&#46; Carbonnel"
                            2 => "C&#46; Robert"
                            3 => "K&#46;M&#46; Kerr"
                            4 => "S&#46; Peters"
                            5 => "J&#46; Larkin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/annonc/mdx225"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Oncol"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "iv119"
                        "paginaFinal" => "iv142"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28881921"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Managing toxicities associated with immune checkpoint inhibitors&#58; consensus recommendations from the Society for Immunotherapy of Cancer &#40;SITC&#41; Toxicity Management Working Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Puzanov"
                            1 => "A&#46; Diab"
                            2 => "K&#46; Abdallah"
                            3 => "C&#46;O&#46; Bingham 3rd"
                            4 => "C&#46; Brogdon"
                            5 => "R&#46; Dadu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s40425-017-0300-z"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Immunother Cancer"
                        "fecha" => "2017"
                        "volumen" => "5"
                        "paginaInicial" => "95"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29162153"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy&#58; American Society of Clinical Oncology Clinical Practice Guideline"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;R&#46; Brahmer"
                            1 => "C&#46; Lacchetti"
                            2 => "B&#46;J&#46; Schneider"
                            3 => "M&#46;B&#46; Atkins"
                            4 => "K&#46;J&#46; Brassil"
                            5 => "J&#46;M&#46; Caterino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2017.77.6385"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2018"
                        "volumen" => "36"
                        "paginaInicial" => "1714"
                        "paginaFinal" => "1768"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29442540"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673603139670"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Overall survival with combined nivolumab and ipilimumab in advanced melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;D&#46; Wolchok"
                            1 => "V&#46; Chiarion-Sileni"
                            2 => "R&#46; Gonzalez"
                            3 => "P&#46; Rutkowski"
                            4 => "J&#46;J&#46; Grob"
                            5 => "C&#46;L&#46; Cowey"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1709684"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "377"
                        "paginaInicial" => "1345"
                        "paginaFinal" => "1356"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28889792"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Larkin"
                            1 => "V&#46; Chiarion-Sileni"
                            2 => "R&#46; Gonzalez"
                            3 => "J&#46;J&#46; Grob"
                            4 => "C&#46;L&#46; Cowey"
                            5 => "C&#46;D&#46; Lao"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1504030"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "23"
                        "paginaFinal" => "34"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26027431"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Weber"
                            1 => "M&#46; Mandala"
                            2 => "M&#46; Del Vecchio"
                            3 => "H&#46;J&#46; Gogas"
                            4 => "A&#46;M&#46; Arance"
                            5 => "C&#46;L&#46; Cowey"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1709030"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "377"
                        "paginaInicial" => "1824"
                        "paginaFinal" => "1835"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28891423"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fatal toxic effects associated with immune checkpoint inhibitors&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;Y&#46; Wang"
                            1 => "J&#46;E&#46; Salem"
                            2 => "J&#46;V&#46; Cohen"
                            3 => "S&#46; Chandra"
                            4 => "C&#46; Menzer"
                            5 => "F&#46; Ye"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaoncol.2018.3923"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Oncol"
                        "fecha" => "2018"
                        "volumen" => "4"
                        "paginaInicial" => "1721"
                        "paginaFinal" => "1728"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30242316"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46;C&#46; Lake"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/QAD.0000000000001599"
                      "Revista" => array:7 [
                        "tituloSerie" => "AIDS"
                        "fecha" => "2017"
                        "volumen" => "31"
                        "paginaInicial" => "2115"
                        "paginaFinal" => "2118"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28906278"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1473309910700128"
                          "estado" => "S300"
                          "issn" => "14733099"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; De Martin"
                            1 => "J&#46;M&#46; Michot"
                            2 => "B&#46; Papouin"
                            3 => "S&#46; Champiat"
                            4 => "C&#46; Mateus"
                            5 => "O&#46; Lambotte"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2018.01.033"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2018"
                        "volumen" => "68"
                        "paginaInicial" => "1181"
                        "paginaFinal" => "1190"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29427729"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange&#58; new settings call for new treatment strategies&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Riveiro-Barciela"
                            1 => "E&#46; Munoz-Couselo"
                            2 => "J&#46; Fernandez-Sojo"
                            3 => "N&#46; Diaz-Mejia"
                            4 => "R&#46; Parra-Lopez"
                            5 => "M&#46; Buti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2018.10.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2019"
                        "volumen" => "70"
                        "paginaInicial" => "564"
                        "paginaFinal" => "566"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30503040"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immunotherapy-related hepatitis&#58; real-world experience from a tertiary centre"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Cheung"
                            1 => "T&#46; Gupta"
                            2 => "M&#46; Payne"
                            3 => "M&#46;R&#46; Middleton"
                            4 => "J&#46;D&#46; Collier"
                            5 => "A&#46; Simmons"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/flgastro-2018-101146"
                      "Revista" => array:6 [
                        "tituloSerie" => "Frontline Gastroenterol"
                        "fecha" => "2019"
                        "volumen" => "10"
                        "paginaInicial" => "364"
                        "paginaFinal" => "371"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31656561"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of resuming anti-PD-1 in patients with immune-related adverse events &#40;irAEs&#41; during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;H&#46; Pollack"
                            1 => "A&#46; Betof"
                            2 => "H&#46; Dearden"
                            3 => "K&#46; Rapazzo"
                            4 => "I&#46; Valentine"
                            5 => "A&#46;S&#46; Brohl"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/annonc/mdx642"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Oncol"
                        "fecha" => "2018"
                        "volumen" => "29"
                        "paginaInicial" => "250"
                        "paginaFinal" => "255"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29045547"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune-related hepatitis related to checkpoint inhibitors&#58; clinical and prognostic factors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Riveiro-Barciela"
                            1 => "A&#46; Barreira-D&#237;az"
                            2 => "J&#46; Vidal-Gonz&#225;lez"
                            3 => "E&#46; Mu&#241;oz-Couselo"
                            4 => "F&#46; Mart&#237;nez-Valle"
                            5 => "L&#46; Viladomiu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Liver Int"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Simonaggio"
                            1 => "J&#46;M&#46; Michot"
                            2 => "A&#46;L&#46; Voisin"
                            3 => "J&#46; Le Pavec"
                            4 => "M&#46; Collins"
                            5 => "A&#46; Lallart"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JAMA Oncol"
                        "fecha" => "2019"
                        "volumen" => "5"
                        "paginaInicial" => "1310"
                        "paginaFinal" => "1317"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Enterocolitis due to immune checkpoint inhibitors&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Soularue"
                            1 => "P&#46; Lepage"
                            2 => "J&#46;F&#46; Colombel"
                            3 => "C&#46; Coutzac"
                            4 => "D&#46; Faleck"
                            5 => "L&#46; Marthey"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gutjnl-2018-316948"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "2056"
                        "paginaFinal" => "2067"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30131322"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Marthey"
                            1 => "C&#46; Mateus"
                            2 => "C&#46; Mussini"
                            3 => "M&#46; Nachury"
                            4 => "S&#46; Nancey"
                            5 => "F&#46; Grange"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ecco-jcc/jjv227"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Crohns Colitis"
                        "fecha" => "2016"
                        "volumen" => "10"
                        "paginaInicial" => "395"
                        "paginaFinal" => "401"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26783344"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune checkpoint inhibition-related colitis&#58; symptoms&#44; endoscopic features&#44; histology and response to management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;H&#46; Geukes Foppen"
                            1 => "E&#46;A&#46; Rozeman"
                            2 => "S&#46; van Wilpe"
                            3 => "C&#46; Postma"
                            4 => "P&#46; Snaebjornsson"
                            5 => "J&#46;V&#46; van Thienen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/esmoopen-2017-000278"
                      "Revista" => array:5 [
                        "tituloSerie" => "ESMO Open"
                        "fecha" => "2018"
                        "volumen" => "3"
                        "paginaInicial" => "e000278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29387476"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gastrointestinal toxicity of immune checkpoint inhibitors&#58; from mechanisms to management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46;A&#46; Samaan"
                            1 => "P&#46; Pavlidis"
                            2 => "S&#46; Papa"
                            3 => "N&#46; Powell"
                            4 => "P&#46;M&#46; Irving"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nrgastro.2018.14"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Gastroenterol Hepatol"
                        "fecha" => "2018"
                        "volumen" => "15"
                        "paginaInicial" => "222"
                        "paginaFinal" => "234"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29512649"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infliximab for ipilimumab-induced colitis&#58; a series of 13 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "N&#46;T&#46; Hillock"
                            1 => "S&#46; Heard"
                            2 => "G&#46; Kichenadasse"
                            3 => "C&#46;L&#46; Hill"
                            4 => "J&#46; Andrews"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajco.12651"
                      "Revista" => array:6 [
                        "tituloSerie" => "Asia Pac J Clin Oncol"
                        "fecha" => "2017"
                        "volumen" => "13"
                        "paginaInicial" => "e284"
                        "paginaFinal" => "e290"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27981760"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46; Abu-Sbeih"
                            1 => "F&#46;S&#46; Ali"
                            2 => "A&#46;R&#46; Naqash"
                            3 => "D&#46;H&#46; Owen"
                            4 => "S&#46; Patel"
                            5 => "G&#46;A&#46; Otterson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.19.00320"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2019"
                        "volumen" => "37"
                        "paginaInicial" => "2738"
                        "paginaFinal" => "2745"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31163011"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;B&#46; Johnson"
                            1 => "R&#46;J&#46; Sullivan"
                            2 => "P&#46;A&#46; Ott"
                            3 => "M&#46;S&#46; Carlino"
                            4 => "N&#46;I&#46; Khushalani"
                            5 => "F&#46; Ye"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaoncol.2015.4368"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Oncol"
                        "fecha" => "2016"
                        "volumen" => "2"
                        "paginaInicial" => "234"
                        "paginaFinal" => "240"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26633184"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;C&#46; Kahler"
                            1 => "T&#46;K&#46; Eigentler"
                            2 => "A&#46; Gesierich"
                            3 => "L&#46; Heinzerling"
                            4 => "C&#46; Loquai"
                            5 => "F&#46; Meier"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00262-018-2134-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Immunol Immunother"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "825"
                        "paginaFinal" => "834"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29487980"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Endocrine-related adverse events following ipilimumab in patients with advanced melanoma&#58; a comprehensive retrospective review from a single institution"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Ryder"
                            1 => "M&#46; Callahan"
                            2 => "M&#46;A&#46; Postow"
                            3 => "J&#46; Wolchok"
                            4 => "J&#46;A&#46; Fagin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1530/ERC-13-0499"
                      "Revista" => array:6 [
                        "tituloSerie" => "Endocr Relat Cancer"
                        "fecha" => "2014"
                        "volumen" => "21"
                        "paginaInicial" => "371"
                        "paginaFinal" => "381"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24610577"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0445"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune-related adverse events with immune checkpoint blockade&#58; a comprehensive review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Michot"
                            1 => "C&#46; Bigenwald"
                            2 => "S&#46; Champiat"
                            3 => "M&#46; Collins"
                            4 => "F&#46; Carbonnel"
                            5 => "S&#46; Postel-Vinay"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2016"
                        "volumen" => "54"
                        "paginaInicial" => "139"
                        "paginaFinal" => "148"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0450"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ipilimumab&#58; a novel immunomodulating therapy causing autoimmune hypophysitis&#58; a case report and review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Juszczak"
                            1 => "A&#46; Gupta"
                            2 => "N&#46; Karavitaki"
                            3 => "M&#46;R&#46; Middleton"
                            4 => "A&#46;B&#46; Grossman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur J Endocrinol"
                        "fecha" => "2012"
                        "volumen" => "167"
                        "paginaInicial" => "1"
                        "paginaFinal" => "5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0455"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ipilimumab-induced hypophysitis&#58; a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;T&#46; Faje"
                            1 => "R&#46; Sullivan"
                            2 => "D&#46; Lawrence"
                            3 => "N&#46;A&#46; Tritos"
                            4 => "R&#46; Fadden"
                            5 => "A&#46; Klibanski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1210/jc.2014-2306"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2014"
                        "volumen" => "99"
                        "paginaInicial" => "4078"
                        "paginaFinal" => "4085"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25078147"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0460"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Endocrine side effects induced by immune checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46;M&#46; Corsello"
                            1 => "A&#46; Barnabei"
                            2 => "P&#46; Marchetti"
                            3 => "L&#46; De Vecchis"
                            4 => "R&#46; Salvatori"
                            5 => "F&#46; Torino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1210/jc.2012-4075"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2013"
                        "volumen" => "98"
                        "paginaInicial" => "1361"
                        "paginaFinal" => "1375"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23471977"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The spectrum&#44; incidence&#44; kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46;S&#46; Scott"
                            1 => "G&#46;V&#46; Long"
                            2 => "A&#46; Guminski"
                            3 => "R&#46;J&#46; Clifton-Bligh"
                            4 => "A&#46;M&#46; Menzies"
                            5 => "V&#46;H&#46; Tsang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1530/EJE-17-0810"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Endocrinol"
                        "fecha" => "2018"
                        "volumen" => "178"
                        "paginaInicial" => "173"
                        "paginaFinal" => "180"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29187509"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Mazarico"
                            1 => "I&#46; Capel"
                            2 => "O&#46; Gimenez-Palop"
                            3 => "L&#46; Albert"
                            4 => "I&#46; Berges"
                            5 => "F&#46; Luchtenberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40618-019-01058-x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Endocrinol Invest"
                        "fecha" => "2019"
                        "volumen" => "42"
                        "paginaInicial" => "1443"
                        "paginaFinal" => "1450"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31093955"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer immunotherapy &#8211; immune checkpoint blockade and associated endocrinopathies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46;J&#46; Byun"
                            1 => "J&#46;D&#46; Wolchok"
                            2 => "L&#46;M&#46; Rosenberg"
                            3 => "M&#46; Girotra"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nrendo.2016.205"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Endocrinol"
                        "fecha" => "2017"
                        "volumen" => "13"
                        "paginaInicial" => "195"
                        "paginaFinal" => "207"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28106152"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Novel cancer therapies and their association with diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;I&#46; Shariff"
                            1 => "S&#46; Syed"
                            2 => "R&#46;A&#46; Shelby"
                            3 => "J&#46; Force"
                            4 => "J&#46;M&#46; Clarke"
                            5 => "D&#46; D&#8217;Alessio"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1530/JME-18-0002"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Mol Endocrinol"
                        "fecha" => "2019"
                        "volumen" => "62"
                        "paginaInicial" => "R187"
                        "paginaFinal" => "R199"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30532995"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Hughes"
                            1 => "N&#46; Vudattu"
                            2 => "M&#46; Sznol"
                            3 => "S&#46; Gettinger"
                            4 => "H&#46; Kluger"
                            5 => "B&#46; Lupsa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2337/dc14-2349"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetes Care"
                        "fecha" => "2015"
                        "volumen" => "38"
                        "paginaInicial" => "e55"
                        "paginaFinal" => "e57"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25805871"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors&#58; a systematic review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46;C&#46; Cappelli"
                            1 => "A&#46;K&#46; Gutierrez"
                            2 => "C&#46;O&#46; Bingham 3rd"
                            3 => "A&#46;A&#46; Shah"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Care Res &#40;Hoboken&#41;"
                        "fecha" => "2017"
                        "volumen" => "69"
                        "paginaInicial" => "1751"
                        "paginaFinal" => "1763"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46;C&#46; Cappelli"
                            1 => "J&#46;R&#46; Brahmer"
                            2 => "P&#46;M&#46; Forde"
                            3 => "D&#46;T&#46; Le"
                            4 => "E&#46;J&#46; Lipson"
                            5 => "J&#46; Naidoo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2018.02.011"
                      "Revista" => array:7 [
                        "tituloSerie" => "Semin Arthritis Rheum"
                        "fecha" => "2018"
                        "volumen" => "48"
                        "paginaInicial" => "553"
                        "paginaFinal" => "557"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29573850"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673620301835"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inflammatory arthritis due to immune checkpoint inhibitors&#58; challenges in diagnosis and treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46;C&#46; Cappelli"
                            1 => "J&#46; Naidoo"
                            2 => "C&#46;O&#46; Bingham 3rd"
                            3 => "A&#46;A&#46; Shah"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2217/imt-2016-0117"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunotherapy"
                        "fecha" => "2017"
                        "volumen" => "9"
                        "paginaInicial" => "5"
                        "paginaFinal" => "8"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28000525"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Roberts"
                            1 => "M&#46; Smylie"
                            2 => "J&#46; Walker"
                            3 => "N&#46;S&#46; Basappa"
                            4 => "Q&#46; Chu"
                            5 => "M&#46; Kolinsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10067-019-04451-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Rheumatol"
                        "fecha" => "2019"
                        "volumen" => "38"
                        "paginaInicial" => "1513"
                        "paginaFinal" => "1519"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30701346"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;J&#46; Braaten"
                            1 => "J&#46;R&#46; Brahmer"
                            2 => "P&#46;M&#46; Forde"
                            3 => "D&#46; Le"
                            4 => "E&#46;J&#46; Lipson"
                            5 => "J&#46; Naidoo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2019-216109"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2020"
                        "volumen" => "79"
                        "paginaInicial" => "332"
                        "paginaFinal" => "338"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31540935"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Lidar"
                            1 => "E&#46; Giat"
                            2 => "D&#46; Garelick"
                            3 => "Y&#46; Horowitz"
                            4 => "H&#46; Amital"
                            5 => "Y&#46; Steinberg-Silman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.autrev.2018.01.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Autoimmun Rev"
                        "fecha" => "2018"
                        "volumen" => "17"
                        "paginaInicial" => "284"
                        "paginaFinal" => "289"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29341936"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab&#58; a case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;T&#46; Kim"
                            1 => "J&#46; Tayar"
                            2 => "V&#46;A&#46; Trinh"
                            3 => "M&#46; Suarez-Almazor"
                            4 => "S&#46; Garcia"
                            5 => "P&#46; Hwu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2017-211560"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "2061"
                        "paginaFinal" => "2064"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28830882"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adjuvant pembrolizumab versus placebo in resected stage III melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;M&#46;M&#46; Eggermont"
                            1 => "C&#46;U&#46; Blank"
                            2 => "M&#46; Mandala"
                            3 => "G&#46;V&#46; Long"
                            4 => "V&#46; Atkinson"
                            5 => "S&#46; Dalle"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1802357"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2018"
                        "volumen" => "378"
                        "paginaInicial" => "1789"
                        "paginaFinal" => "1801"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29658430"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46;J&#46; Moslehi"
                            1 => "J&#46;E&#46; Salem"
                            2 => "J&#46;A&#46; Sosman"
                            3 => "B&#46; Lebrun-Vignes"
                            4 => "D&#46;B&#46; Johnson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(18)30533-6"
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2018"
                        "volumen" => "391"
                        "paginaInicial" => "933"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29536852"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune checkpoint inhibitor-associated myositis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Anquetil"
                            1 => "J&#46;E&#46; Salem"
                            2 => "B&#46; Lebrun-Vignes"
                            3 => "D&#46;B&#46; Johnson"
                            4 => "A&#46;L&#46; Mammen"
                            5 => "W&#46; Stenzel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.118.035898"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2018"
                        "volumen" => "138"
                        "paginaInicial" => "743"
                        "paginaFinal" => "745"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30359135"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Moreira"
                            1 => "C&#46; Loquai"
                            2 => "C&#46; Pfohler"
                            3 => "K&#46;C&#46; Kahler"
                            4 => "S&#46; Knauss"
                            5 => "M&#46;V&#46; Heppt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2018.09.033"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2019"
                        "volumen" => "106"
                        "paginaInicial" => "12"
                        "paginaFinal" => "23"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30453170"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Touat"
                            1 => "T&#46; Maisonobe"
                            2 => "S&#46; Knauss"
                            3 => "O&#46; Ben Hadj Salem"
                            4 => "B&#46; Hervier"
                            5 => "K&#46; Aure"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1212/WNL.0000000000006124"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neurology"
                        "fecha" => "2018"
                        "volumen" => "91"
                        "paginaInicial" => "e985"
                        "paginaFinal" => "e994"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30089619"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Abatacept for severe immune checkpoint inhibitor-associated myocarditis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;E&#46; Salem"
                            1 => "Y&#46; Allenbach"
                            2 => "A&#46; Vozy"
                            3 => "N&#46; Brechot"
                            4 => "D&#46;B&#46; Johnson"
                            5 => "J&#46;J&#46; Moslehi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMc1901677"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2019"
                        "volumen" => "380"
                        "paginaInicial" => "2377"
                        "paginaFinal" => "2379"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31189043"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;C&#46; Santini"
                            1 => "H&#46; Rizvi"
                            2 => "A&#46;J&#46; Plodkowski"
                            3 => "A&#46; Ni"
                            4 => "M&#46;E&#46; Lacouture"
                            5 => "M&#46; Gambarin-Gelwan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1158/2326-6066.CIR-17-0755"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Immunol Res"
                        "fecha" => "2018"
                        "volumen" => "6"
                        "paginaInicial" => "1093"
                        "paginaFinal" => "1099"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29991499"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Myasthenia gravis&#58; an emerging toxicity of immune checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "D&#46; Makarious"
                            1 => "K&#46; Horwood"
                            2 => "J&#46;I&#46;G&#46; Coward"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2017.05.041"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2017"
                        "volumen" => "82"
                        "paginaInicial" => "128"
                        "paginaFinal" => "136"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28666240"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neurological toxicities associated with immune-checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46; Touat"
                            1 => "D&#46; Talmasov"
                            2 => "D&#46; Ricard"
                            3 => "D&#46; Psimaras"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/WCO.0000000000000503"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Neurol"
                        "fecha" => "2017"
                        "volumen" => "30"
                        "paginaInicial" => "659"
                        "paginaFinal" => "668"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28938341"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical spectrum of neuromuscular complications after immune checkpoint inhibition"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Puwanant"
                            1 => "M&#46; Isfort"
                            2 => "D&#46; Lacomis"
                            3 => "S&#46;A&#46; Zivkovic"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.nmd.2018.11.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neuromuscul Disord"
                        "fecha" => "2019"
                        "volumen" => "29"
                        "paginaInicial" => "127"
                        "paginaFinal" => "133"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30638612"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inflammatory and infectious syndromes associated with cancer immunotherapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;A&#46; Fishman"
                            1 => "J&#46;I&#46; Hogan"
                            2 => "M&#46;V&#46; Maus"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/cid/ciy1025"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2019"
                        "volumen" => "69"
                        "paginaInicial" => "909"
                        "paginaFinal" => "920"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30520987"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Toxicity management with combination chemotherapy and programmed death 1&#47;programmed death ligand 1 inhibitor therapy in advanced lung cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "B&#46; Hoffner"
                            1 => "N&#46;B&#46; Leighl"
                            2 => "M&#46; Davies"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ctrv.2020.101979"
                      "Revista" => array:5 [
                        "tituloSerie" => "Cancer Treat Rev"
                        "fecha" => "2020"
                        "volumen" => "85"
                        "paginaInicial" => "101979"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32078962"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous&#44; gastrointestinal&#44; hepatic&#44; endocrine&#44; and renal side-effects of anti-PD-1 therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Hofmann"
                            1 => "A&#46; Forschner"
                            2 => "C&#46; Loquai"
                            3 => "S&#46;M&#46; Goldinger"
                            4 => "L&#46; Zimmer"
                            5 => "S&#46; Ugurel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2016.02.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2016"
                        "volumen" => "60"
                        "paginaInicial" => "190"
                        "paginaFinal" => "209"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27085692"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;B&#46; Cortazar"
                            1 => "K&#46;A&#46; Marrone"
                            2 => "M&#46;L&#46; Troxell"
                            3 => "K&#46;M&#46; Ralto"
                            4 => "M&#46;P&#46; Hoenig"
                            5 => "J&#46;R&#46; Brahmer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.kint.2016.04.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "2016"
                        "volumen" => "90"
                        "paginaInicial" => "638"
                        "paginaFinal" => "647"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27282937"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Renal complications of immune checkpoint blockade"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "N&#46; Murakami"
                            1 => "S&#46; Motwani"
                            2 => "L&#46;V&#46; Riella"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.currproblcancer.2016.12.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Probl Cancer"
                        "fecha" => "2017"
                        "volumen" => "41"
                        "paginaInicial" => "100"
                        "paginaFinal" => "110"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28189263"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tumor regression and allograft rejection after administration of anti-PD-1"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Lipson"
                            1 => "S&#46;M&#46; Bagnasco"
                            2 => "J&#46; Moore Jr&#46;"
                            3 => "S&#46; Jang"
                            4 => "M&#46;J&#46; Patel"
                            5 => "A&#46;A&#46; Zachary"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMc1509268"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2016"
                        "volumen" => "374"
                        "paginaInicial" => "896"
                        "paginaFinal" => "898"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26962927"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack500248"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0235" class="elsevierStylePara elsevierViewall">English writing support was provided by Fidelma Greaves&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23870206/0000015500000012/v1_202012131835/S2387020620305520/v1_202012131835/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "44147"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Review"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015500000012/v1_202012131835/S2387020620305520/v1_202012131835/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620305520?idApp=UINPBA00004N"
]
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2023 March 5 1 6
2020 December 5 2 7

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos